Ring Therapeutics Announces the Appointment of Industry Leaders to its Board of Directors
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Ring Therapeutics, a life sciences company founded…
News
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis
WARREN, N.J., March 17, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing…
Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree
-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™ -$100 million in gross…
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3…
Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging
Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals’…
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical…
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., March 17,…
Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors
PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a…
Clearmind Medicine Announces Positive Results on CMND-100 trials
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in…
CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical…
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr)…
Century Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results and Provides Business Updates
IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial…
InMed Announces Management Changes
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022…
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the…
Tilray Medical Expands Offering in Malta and Launches First Medical Cannabis Oil Products in Market
LEAMINGTON, Ontario, March 17, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”)…
ProMIS Neurosciences Announces Fiscal Year 2021 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc….